Oppenheimer analyst Jeff Jones maintains $Pharvaris (PHVS.US)$ with a buy rating, and maintains the target price at $38.
According to TipRanks data, the analyst has a success rate of 36.7% and a total average return of 6.4% over the past year.

$Pharvaris (PHVS.US)$ Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
$Amgen (AMGN.US)$ Inc. is in advanced talks to buy drug company $Horizon Therapeutics (HZNP.US)$, according to people familiar with the matter, in a takeover likely to be valued at well over $20 billion and mark the largest healthcare merger of the year.
$ROCHESTER RESOURCES LTD (RCTFF.US)$Holding AG presented new data from a ...

$HTG Molecular Diagnostics (HTGM.US)$ Everyone seems to have slept on this one $Baudax Bio (BXRX.US)$ $Ambrx Biopharma (AMAM.US)$ $Pharvaris (PHVS.US)$

$Pharvaris (PHVS.US)$ back in aug because of fda halt this dropped from 18 to under 10. now that it has succeeded, possible increase back?

$Pharvaris (PHVS.US)$ Oops now is a gainer

$Pharvaris (PHVS.US)$ Creeping back up

$Pharvaris (PHVS.US)$ id get out and bring your money over to smmt. to many walls here its going to be a red day for sure. happy friday

$Pharvaris (PHVS.US)$ down heavy on this but getting some back with $Baudax Bio (BXRX.US)$  f*** the pumper